High-Dose IV Immunoglobulin in Juvenile Myasthenia
Abstract
Ten children (median age, 13 years; range, 3-18 yrs) with juvenile myasthenia gravis were treated with high-dose intravenous immunoglobulin (2 gm/kg body wt) and prospectively evaluated for 5 years at the Department of Neurology, Wayne State University, Children’s Hospital of Michigan, Detroit, MI.
DOI: https://doi.org/10.15844/pedneurbriefs-14-4-3 | Journal eISSN: 2166-6482
Language: English
Page range: 26 - 26
Published on: Apr 1, 2000
Published by: Pediatric Neurology Briefs Publishers
In partnership with: Paradigm Publishing Services
© 2000 J Gordon Millichap, published by Pediatric Neurology Briefs Publishers
This work is licensed under the Creative Commons Attribution 4.0 License.